Part V
In Vivo Biodistribution Using
PET and SPECT
Chapter 15: Preclinical PET and SPECT for Radionanomedicine
Chapter 16: Tracer Kinetic in Radionanomedicine
In this part, readers will find the very concise summary of what tracer technology
can give the in vivo behavior of administered radionanomedicines, in other words,
pharmacokinetics of radionanomaterials. The advantages of tracing radionanomaterials using PET and SPECT are 1) seeing their whereabouts serially, 2) visualization in a tomographic way, with attenuation correction in humans and 3) even
quantification. In Chap. 15, the readers can find the basic facts about PET and
SPECT associated with CT or MRI (PET/CT or PET/MRI) especially expecting
human clinical applications of radionanomedicines. To understand the quantifiability of PET and SPECT, one needs to know the acquisition and reconstruction of
serial images with quantifiable accuracy and precision in Chap. 15. With the
acquired images, we do tracer kinetic modeling and find the rate constants or
representative parameters to explain the biodistribution or uptake/excretion of
radiolabeled nanomaterials in exact fashion, and this is called quantification. This
quantification is detailed in such a great abstraction not losing the comprehensiveness in this chapter. After browsing the first part of summary of wellestablished knowledge of tracer kinetics acquired from radiolabeled small molecule
PET, the readers are going to learn how the tracer kinetic studies helped understand
the factors contributing the uptake and excretion. Once pharmacokinetic understanding is completed using PET or SPECT tracer kinetic studies, one can now turn
to the exact understanding of pharmacodynamics to explain biological effect of
tumor regression or regenerative success.
In Vivo Biodistribution Using
PET and SPECT
Chapter 15: Preclinical PET and SPECT for Radionanomedicine
Chapter 16: Tracer Kinetic in Radionanomedicine
In this part, readers will find the very concise summary of what tracer technology
can give the in vivo behavior of administered radionanomedicines, in other words,
pharmacokinetics of radionanomaterials. The advantages of tracing radionanomaterials using PET and SPECT are 1) seeing their whereabouts serially, 2) visualization in a tomographic way, with attenuation correction in humans and 3) even
quantification. In Chap. 15, the readers can find the basic facts about PET and
SPECT associated with CT or MRI (PET/CT or PET/MRI) especially expecting
human clinical applications of radionanomedicines. To understand the quantifiability of PET and SPECT, one needs to know the acquisition and reconstruction of
serial images with quantifiable accuracy and precision in Chap. 15. With the
acquired images, we do tracer kinetic modeling and find the rate constants or
representative parameters to explain the biodistribution or uptake/excretion of
radiolabeled nanomaterials in exact fashion, and this is called quantification. This
quantification is detailed in such a great abstraction not losing the comprehensiveness in this chapter. After browsing the first part of summary of wellestablished knowledge of tracer kinetics acquired from radiolabeled small molecule
PET, the readers are going to learn how the tracer kinetic studies helped understand
the factors contributing the uptake and excretion. Once pharmacokinetic understanding is completed using PET or SPECT tracer kinetic studies, one can now turn
to the exact understanding of pharmacodynamics to explain biological effect of
tumor regression or regenerative success.